Chargement en cours...
ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial
BACKGROUND: Over the last few years, the use of phosphodiesterase type 5 (PDE5) inhibitors has been expanded to management of various cardiovascular disorders beyond pulmonary arterial hypertension. This study is designed to investigate the ability of udenafil, a newly developed long-acting PDE5 inh...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3694004/ https://ncbi.nlm.nih.gov/pubmed/23799908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-14-188 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|